- Zymeworks Inc. (ZYME, Financial) appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development.
- Dr. Mekan will lead Zymeworks' clinical development strategy for oncology and global regulatory affairs.
- Her appointment strengthens Zymeworks' focus on developing innovative treatments for difficult-to-treat cancers.
Zymeworks Inc. (ZYME), a leading clinical-stage biotechnology company, has announced the appointment of Dr. Sabeen Mekan as Senior Vice President of Clinical Development. Dr. Mekan will be instrumental in shaping the clinical development strategy for Zymeworks' oncology portfolio and managing global regulatory affairs. Her extensive background includes 18 years of experience in hematology and oncology, spanning academic research, clinical practice, and the biopharmaceutical industry.
Dr. Mekan's previous career highlights include serving as Executive Director at Gilead Sciences, as well as holding senior medical positions at Daiichi Sankyo and Bristol-Myers Squibb. At Zymeworks, she will support the development of next-generation antibody-drug conjugates and multispecific antibody therapeutics targeting gynecological, thoracic, and digestive system cancers.
In conjunction with this leadership change, Dr. Jeff Smith will continue his role as Executive Vice President & Chief Medical Officer, focusing on the company's expanding R&D portfolio in autoimmune and inflammatory diseases. Additionally, Barbara Schaeffler has been promoted to Senior Vice President of Clinical Development Operations.
Zymeworks remains committed to advancing a robust pipeline of groundbreaking therapeutic candidates, addressing significant unmet medical needs in cancer, inflammation, and autoimmune diseases. The appointment of Dr. Mekan underscores the company's commitment to enhancing its clinical-stage oncology portfolio and diversifying into autoimmune and inflammatory diseases.
